Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors

References

• Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation and cancer. Cancer J. 2014;20:181–189.
   Web of Science ®Google Scholar
• Fusco F, Arcaniolo D, Restaino A, et al. Prevalence of chronic prostatic inflammation based on clinical diagnostic criteria in a real-practice setting: a nation-wide observational study. Minerva Urol Nefrol. 2017;69:509–518.
   Web of Science ®Google Scholar
• Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–237.
   PubMed Web of Science ®Google Scholar
• Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res. 2017;23:6764–6770.
   PubMed Web of Science ®Google Scholar
• Porcaro AB, Tafuri A, Novella G, et al. Inverse association of prostatic chronic inflammation among prostate cancer tumor grade groups: retrospective study of 738 consecutive cases elected to a first random biopsy set. Urol Int. 2018;100:456–462.
   Web of Science ®Google Scholar
• Cheng I, Witte JS, Jacobsen SJ, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California men’s health study. PLoS One. 2010;5:e8736.
   Web of Science ®Google Scholar
• Gurel B, Lucia MS, Thompson IM Jr, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014;23:847–856.
   Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–252.
   PubMed Web of Science ®Google Scholar
• Vasavada SR, Dobbs RW, Kajdacsy-Balla AA, et al. Inflammation on prostate needle biopsy is associated with lower prostate cancer risk: a meta-analysis. J Urol. 2018;199:1174–1181.
   Google Scholar
• Amini E, Pishgar F, Ayati M, et al. Transition zone prostate-specific antigen density could better guide the rebiopsy strategy in men with prostate inflammation at initial biopsy. Urology. 2015;86:985–990.
   Web of Science ®Google Scholar
• Bassett WW, Bettendorf DM, Lewis JM, et al. Chronic periglandular inflammation on prostate needle biopsy does not increase the likelihood of cancer on subsequent biopsy. Urology. 2009;73:845–849.
   Web of Science ®Google Scholar
• Abdel-Meguid TA, Mosli HA, Al-Maghrabi JA. Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer. Saudi Med J. 2009;30:1563–1567.
   Web of Science ®Google Scholar
• Karakiewicz PI, Benayoun S, Begin LR, et al. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract. 2007;61:425–430.
   PubMed Web of Science ®Google Scholar
• Benedetti I, Bettin A, Reyes N. Inflammation and focal atrophy in prostate needle biopsy cores and association to prostatic adenocarcinoma. Ann Diagn Pathol. 2016;24:55–61.
   Web of Science ®Google Scholar
• MacLennan GT, Eisenberg R, Fleshman RL, et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol. 2006;176:1012–1016.
   PubMed Web of Science ®Google Scholar
• Hu JC, Palapattu GS, Kattan MW, et al. The association of selected pathological features with prostate cancer in a single-needle biopsy accession. Hum Pathol. 1998;29:1536–1538.
   Web of Science ®Google Scholar
• Moreira DM, de O Freitas DM, Nickel JC, et al. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens. Prostate Cancer Prostatic Dis. 2017;20:413–417.
   Web of Science ®Google Scholar
• Porcaro AB, Novella G, de Luyk N, et al. Intraprostatic chronic inflammation is associated with a reduced risk of prostate cancer in patients elected to a first random biopsy set. Tumori. 2017;103:475–482.
   Web of Science ®Google Scholar
• Porcaro AB, Mattevi D, Novella G, et al. Associations of transitional zone volume with intraprostatic chronic inflammation and prostate cancer risk in patients undergoing a first random biopsy set. Curr Urol. 2017;11:85–91.
   Google Scholar
• Porcaro AB, Cavicchioli F, Mattevi D, et al. Clinical factors of disease reclassification or progression in a contemporary cohort of prostate cancer patients elected to active surveillance. Urol Int. 2017;98:32–39.
   Web of Science ®Google Scholar
• Porcaro A, Inverardi D, Corsi P, et al. Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer. Minerva Urol Nefrol. 2020;72:66–71.
   Web of Science ®Google Scholar
• Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546–7554.
   PubMed Web of Science ®Google Scholar
• Porcaro AB, Corsi P, de Luyk N, et al. Prostate volume index stratified prostate cancer risk in patients elected to a first random biopsy set. Tumori. 2017;103:374–379.
   Web of Science ®Google Scholar
• Ung JO, San Francisco IF, Regan MM, et al. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol. 2003;169:130–135.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106–117.
   PubMed Web of Science ®Google Scholar
• Lopez DS, Advani S, Tsilidis KK, et al. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk? Transl Androl Urol. 2017;6:566–579.
   PubMed Web of Science ®Google Scholar
• Wang K, Chen X, Bird VY, et al. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients’ data with prostatic diseases. Int J Cancer. 2017;141:1783–1793.
   Web of Science ®Google Scholar
• Cappuccini F, Stribbling S, Pollock E, et al. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016;65:701–713.
   PubMed Web of Science ®Google Scholar
• Tong S, Cardinal HN, McLoughlin RF, et al. Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging. Ultrasound Med Biol. 1998;24:673–681.
   Web of Science ®Google Scholar
• Porcaro AB, Tafuri A, Sebben M, et al. Prostate volume index is able to differentiate between prostatic chronic inflammation and prostate cancer in patients with normal digital rectal examination and prostate-specific antigen values <10 ng/mL: results of 564 biopsy naive cases. Urol Int. 2019;103:415–422.
   Web of Science ®Google Scholar